Patients with 'Loss-of-Function' CYP2C9 alleles (*2 or *3) require which adjustment to their Warfarin therapy?
Show answer and explanation
Correct answer: A lower starting dose
CYP2C9 is the primary enzyme that metabolizes the more potent S-enantiomer of warfarin. Reduced enzyme activity leads to higher drug levels and an increased risk of bleeding, necessitating a lower initial and maintenance dose.
Keep practicing
More Pharmacogenomics questions
- Which genetic variation is linked to an increased risk of 'Torsades de Pointes' when taking QT-prolonging drugs?
- In pharmacogenomics, the term 'phenoconversion' refers to:
- Genetic testing for which marker is recommended to avoid hypersensitivity to Carbamazepine in patients of European descent, as an alternati…
- Which of the following describes a 'Single Nucleotide Polymorphism' (SNP)?
- Patients who are 'Poor Metabolizers' of CYP2D6 are at increased risk of therapeutic failure when treated with which prodrug?
- The presence of the HLA-B*15:02 allele is a strong predictor of Stevens-Johnson Syndrome (SJS) in patients taking which medication?